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ABSTRACT
Hypertension (HTN) is frequently associated with the use of angiogenesis 
inhibitors targeting the vascular endothelial growth factor pathway and appears 
to be a generalized effect of this class of agent. We investigated the phenomenon 
in 61 patients with advanced hepatocellular carcinoma (HCC) receiving sorafenib. 
Blood pressure and plasma electrolytes were measured on days 1 and 15 of the 
treatment. Patients with sorafenib-induced HTN had a better outcome than those 
without HTN (disease control rate: 63.4% vs. 17.2% (p=0.001); progression-free 
survival 6.0 months (95% CI 3.2-10.1) vs. 2.5 months (95% CI 1.9-2.6) (p<0.001) 
and overall survival 14.6 months (95% CI9.7-19.0) vs. 3.9 months (95% CI 3.1-8.7) 
(p=0.003). Sodium levels were generally higher on day 15 than at baseline (+2.38, 
p<0.0001) in the group of responders (+4.95, p <0.0001) compared to patients 
who progressed (PD) (+0.28, p=0.607). In contrast, potassium was lower on day 
14 (-0.30, p=0.0008) in the responder group (-0.58, p=0.003) than in those with 
progressive disease (-0.06, p=0.500). The early onset of hypertension is associated 
with improved clinical outcome in HCC patients treated with sorafenib. Our data are 
suggestive of an activation of the renin-angiotensin system in patients with advanced 
disease who developed HTN during sorafenib treatment.
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INTRODUCTION
Hepatocellular carcinoma (HCC), the most common 
primary liver cancer, is increasing in incidence. It currently 
represents the fifth most common malignancy worldwide 
and the third leading cause of cancer-related death [1]. 
The introduction of sorafenib has positively changed 
the clinical landscape of the disease despite its limited 
efficacy and moderate toxicity in a substantial percentage 
of patients [2-7].
Hypertension (HTN) is frequently associated with 
the use of angiogenesis inhibitors targeting the vascular 
endothelial growth factor (VEGF) pathway and appears 
to be a generalized effect of this class of agent [8-14]. 
Physiologically, HTN develops when VEGF stimulates 
the production of nitric oxide and prostacyclins in 
vascular endothelial cells [15-17], inhibiting vasodilatory 
mechanisms, increasing peripheral vascular resistance 
and leading to higher blood pressure (BP). Moreover, 
vasoconstriction determines a decrease in the glomerular 
filtration rate and an increase in sodium and water retention 
by the kidneys, as occurs in pre-eclampsia which has been 
linked to placental-derived soluble antiangiogenic factors 
including VEGF [18,19].
The inhibition of VEGFR-2 by sorafenib leads to 
a decrease in phosphoinositide 3-kinase (PI3K), Akt, 
endothelium-derived nitric oxide synthase (eNOS) 
expression and the production of the potent vasodilator 
nitric oxide [20-22].
Based on these observations, we performed 
a retrospective analysis to evaluate whether the 
development of HTN and changes in serum electrolytes 
in patients with metastatic HCC receiving sorafenib are 
associated with the antitumor efficacy of the drug.
RESULTS
Patient characteristics
From 1 July 2011 to 25 March 2015, 61 consecutive 
patients with Child-Pugh A HCC receiving sorafenib 
were available for our analysis. Fifty-one (84.3%) were 
males and 10 (15.7%) females, with a median age at 
diagnosis of 72 years (range 28-87). Median follow-up 
was 34 months (range 1-45). Seven patients had BCLC-B 
and 54 had BCLC-C. Twenty (32%) patients had 
previously undergone transarterial chemo-embolisation 
(TACE). The most common liver disease etiologies were 
hepatitis C (50.8%), alcoholic liver disease (10.2%), fatty 
liver disease (15%) and hepatitis B (15.2%) (Table 1). 
The dose of sorafenib was reduced in 32 (52%) patients, 
9 of whom had grade 3 HTN, 6 grade 3 HTN and grade 
2 skin toxicity, 7 grade 2-3 skin toxicity, 5 grade 2-3 
asthenia, and 5 grade 2-3 diarrhea. Median PFS was 2.8 
months (95% CI 2.5-3.7) and median OS was 8.7 months 
(95% CI 5.7-13.9).
Hypertension and clinical outcome
Patients who developed HTN after 15 days of 
treatment had a median PFS of 6 months (95% CI 3.2-10.1) 
compared to 2.5 months (95% CI 1.9-2.6) for those who did 
not (HR=0.24, 95% CI 0.13-0.46, p<0.0001) (Figure 1A). 
HTN patients had a median OS of 14.6 months (95% CI 9.7-
Table 1: Patient characteristics (n=61)
Variable No. (%)
Median age, years (range) 72 (28-87)
Gender
 Male 51 (83.6)
 Female 10 (16.4)
ECOG PS 
 0 37 (60.7)
 1 24 (39.3)
Etiology
 Hepatitis C 30 (50.8)
 Hepatitis B 9 (15.2)
 Alcoholic liver disease 6 (10.2)
 Metabolic syndrome 10 (16.9)
 Other 4 (6.8)
 Missing 2
BCLC Staging
 B 7 (11.5)
 C 54 (88.5)
Vascular invasion
 No 14 (40.0)
 Si 21 (60.0)
 Missing 26
Pretreatment blood pressure
 Mean systolic value (SD) 118.44 (11.82)
 Mean diastolic value (SD) 76.15 (9.24)
BCLC, Barcelona Clinic Liver Cancer; SD, standard 
deviation
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19.0) compared to 3.9 months (95% CI 3.1-8.7) for those in 
the non HTN group (HR=0.41, 95% CI 0.23-0.74, p=0.003) 
(Figure 1B). DCR in HTN patients was 63.4% compared to 
17.2% in those without HTN (p=0.001) (Table 2).
Figure 2 shows the mean values of SBP and DBP at 
baseline and on day 15 of the first cycle of sorafenib with 
respect to objective response. SBP increased significantly 
from baseline to day 15 of the first cycle of sorafenib, 
with a mean increase of 31 mm Hg in patients showing 
an objective response (p=0.003), 22.2 mm Hg in those 
with SD (p=0.004), and 6.6 mm Hg in PD patients 
(p=0.022).
DBP did not change significantly from baseline to day 
15 of the first cycle of sorafenib in any group, regardless of 
objective response. Median PFS was 2.1 months (95% CI 
0.9-2.6) in patients with grade 1 HTN, 5.2 months (95% CI 
1.2-10.8) in those with grade 2 HTN, and 8.5 months (95% 
CI 3.2-15.3) (p<0.0001) in the grade 3 HTN group (Table 3 
and Figure 1C). Median OS was 3.6 months (95% CI 1.1-
8.7) in grade 1 HTN patients, 15.6 months (95% CI 2.0-
23.0) in those with grade 2 HTN, and 13.2 months (95% CI 
5.7-34.2) (p<0.011) in the grade 3 HTN group (Table 3 and 
Figure 1D). Comorbidities that could potentially influence 
BP were similar in the two cohorts.
After adjusting for clinical covariates (age, gender, 
etiology, BCLC stage, ECOG performance status, toxicity, 
treatment duration and previous TACE), HTN remained 
an independent prognostic factor for both PFS (HR=0.21, 
95% CI 0.09-0.48, p= 0.0002) and OS (HR=0.41, 95% CI 
0.17-0.96, p=0.041).
Hypertension and electrolyte changes
Comparing electrolyte values at baseline and on day 
15 (Table 4), we observed a reduction in potassium levels 
(mean 5.7%) and an increase in sodium levels (average 
1.6%) that were more marked in DCR patients (defined as 
responders) than in those with PD. Considering the trend of 
average electrolyte values of the 2 blood tests, the t-test for 
paired data showed that the absolute values of sodium on 
day 15 were generally higher than those at baseline (+2.38, 
p<0.0001) in DCR patients (+4.95, p<0.0001) compared 
to the PD group (+0.28, p=0.607). Potassium showed the 
same trend, with generally lower average values on day 15 
Figure 1: Progression-free and overall survival in patients with or without hypertension (HTN) A, C. and according to 
the grade of hypertension B, D.
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Table 2: Best objective response to sorafenib
All patients (n=61) 
No. (%)
No HTN (n=35) 
No. (%)
HTN (n=26) 
No. (%)
p
CR 1 (2.0) 0 1 (4.5)
PR 3 (5.9) 0 3 (13.6)
SD 15 (29.4) 5 (17.2) 10 (45.5)
PD 32 (62.7) 24 (82.8) 8 (36.4)
Missing/NE 10 6 4
DCR (CR+PR+SD) 19 (37.3) 5 (17.2) 14 (63.4) 0.001
HTN, hypertension; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not 
evaluable; DCR, disease control rate
Figure 2: Mean values of systolic and diastolic blood pressure at baseline and on day 15 of the first cycle of sorafenib 
according to objective response. CR+ PR: complete response plus partial response; SD: stationary disease; PD: progressive disease.
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Table 3: Progression-free and overall survival evaluated according to the hypertension toxicity (grade)
Grade No. patients No. events Median PFS (months) 
(95% CI)
p HR (95% 
CI)
p
0 26 24 2.5 (1.8-2.8) 1.00
1 10 10 2.1 (0.9-2.6)
0.88 
(0.41-
1.87)
2 10 9 5.2 (1.2-10.8)
0.30 
(0.13-
0.71)
3 15 12 8.5 (3.2-15.3) <0.0001
0.16 
(0.07-
0.37)
<0.0001
Grade No. patients No. events Median OS (months) (95% CI) p
HR (95% 
CI) p
0 26 21 5.8 (3.1-10.4) 1.00
1 10 10 3.6 (1.1-8.7)
0.96 
(0.45-
2.08)
2 10 9 15.6 (2.0-23.0)
0.45 
(0.20-
1.01)
3 15 11 13.2 (5.7-34.2) 0.011
0.32 
(0.14-
0.71)
0.016
HZ, hazard ratio
Table 4: Variation in sodium and potassium levels as a function of best objective response to sorafenib
Percentage variation after 15 days
No. patients Median value (IQR) Median value (SD)
Sodium
Overall 61 0 (-3 to 12.3) 1.6 (2.8)
DCR 19 3 (0 to 8.2) 3.3 (2.5)
PD 32 0 (-3 to 5.1) 0.25 (1.8)
 p (between DCR and PD) <0.00011
Potassium
Overall 61 -2 (-41 to 38.13) -5.7 (13.4)
DCR 19 -16 (-37 to 38.20) -11.1 (16.0)
PD 32 0.50 (-41 to 14. 7) -1.06 (10.2)
 p (between DCR and PD) 0.00071
IQR, interquartile range; DCR, disease control rate; PD, progressive disease; SD, standard deviation
1 Wilcoxon median test
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than at baseline (-0.30, p=0.0008) in the DCR group (-0.58, 
p=0.003) than in PD patients (-0.06, p=0.500).
DISCUSSION
In this retrospective study, a correlation emerged 
between the development of HTN during treatment 
with sorafenib and survival of advanced HCC patients. 
Patients with HTN also had a better DCR than those 
without HTN. Furthermore, we noticed that the higher 
the BP, especially systolic, the better the response to 
treatment with sorafenib. Figure 3 shows the hypothetic 
effect of VEGFR on blood vessel tone in patients 
(A) without sorafenib-induced HTN and (B) with 
sorafenib-induced HTN. The activation of VEGFR-2 via 
phosphoinositide 3-kinase (PI3K) and its downstream 
serine protein kinase Akt stimulates endothelium-derived 
nitric oxide synthase (eNOS), produce nitric oxide (NO), 
a potent vasodilatator. NO also exerts an inhibitory 
effect on the vasoconstrictor endothelin-1 (ET-1) (panel 
A). In patients treated with sorafenib, the inhibition of 
VEGFR-2 is thought to reduce the bioavailability of 
NO, resulting in vasoconstriction and consequent HTN 
[24-27].
Although a correlation between HTN and 
response to sorafenib in HCC patients has already been 
reported in some studies [28, 29], it was established on 
the basis of grade of toxicity alone by assessing HTN 
one or 2 months after the start sorafenib. Conversely, 
we evaluated SBP and DBP separately after only 15 
days of treatment and not only in terms of grade of 
toxicity.
Our data revealed a correlation between the 
change in electrolyte values and sorafenib-related 
HTN. It can be hypothesized that sorafenib blocks 
the VEGF receptor, inducing vasoconstriction in the 
kidneys, activating the renin-angiotensin-aldosterone 
system and increasing the production of renin. Renin 
converts angiotensin I into angiotensin II, leading to 
water retention, hypernatremia and hypokalemia [30] 
(Figure 4). Our data suggest that HTN in HCC patients 
undergoing treatment with sorafenib could be treated 
with ACE inhibitors.
One strength of our study lies in the detailed 
information it provides on patient characteristics and 
follow up. However, the study also has some limitations. 
Despite being a retrospective evaluation, cases were 
selected consecutively to minimize bias. Secondly, 
as there was no control arm (patients not receiving 
sorafenib), a clear distinction between the prognostic and 
predictive role of HTN in terms of survival could not 
be made. Although multivariable analysis indicated that 
HTN was an independent variable, it cannot be ruled out 
that results were biased by the relatively small sample 
number.
In conclusion, sorafenib-related HTN is potentially 
predictive factor associated with significantly longer OS 
and PFS in patients with advanced HCC.
Figure 3: Hypothetic effect of vascular endothelial growth factor receptor (VEGFR) on blood vessel tone in patients A. 
without sorafenib-induced hypertension and B. with sorafenib-induced hypertension.
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PATIENTS AND METHODS
This retrospective cohort study included all the 
patients treated for HCC between 1st July 2013 and 25th 
March 2015 at our institute (IRST IRCCS) in Meldola, 
Italy. Seventy-eight patients with advanced or intermediate 
stage HCC that was refractory or no longer amenable to 
locoregional therapies (according to American Association 
for the Study of Liver Diseases guidelines) were eligible 
for our analysis. All patients received a standard sorafenib 
regimen (400 mg bid continuously), dose reductions being 
made if deemed clinically necessary. Follow-up consisted 
of CT/MRI scanning every 8 weeks or as clinically 
indicated. Tumor response was evaluated by modified 
Response Evaluation Criteria in Solid Tumors (mRECIST) 
[23]. Treatment with sorafenib was continued until disease 
progression, unacceptable toxicity or death. Sorafenib was 
suspended in patients experiencing grade 4 treatment-
related HTN (according to Common Terminology Criteria 
for Adverse Events, CTCAE, v4.03), while a dose 
reduction was recommended for patients with grades 1 to 
3 HTN when blood pressure was difficult to control.
Patients were monitored as follows: days 1, 15, 
28 and 60 of cycle 1, and every 2 months thereafter. 
Disease progression was assessed using mRECIST. 
Electrolytes were measured on days 1 and 15 of 
treatment. HCC patients without cirrhosis were excluded 
from the study. BP was measured on days 1 and 15 of 
treatment. Patients who had uncontrolled blood pressure 
at baseline (systolic BP >140 mm Hg and diastolic BP 
>90 mm Hg) were excluded from the study. HTN was 
defined as either a maximum or mean systolic BP (SBP) 
of at least 140 mm Hg or diastolic BP (DBP) of at least 
90 mm Hg. HTN grade was defined according to the 
Common Terminology Criteria for Adverse Events 
(CTCAE) of the National Cancer Institute, version 4.03 
of 14th June 2010.
This study was approved by the local Ethics 
Committee and informed consent was obtained from all 
patients.
Efficacy and safety assessments
The primary objective of this study was to compare 
progression-free survival (PFS) between patients who 
developed HTN and those who showed no signs of HTN 
during the first 15 days of treatment with sorafenib. 
Our second objective was to evaluate changes in blood 
electrolytes (sodium and potassium) in patients with HTN 
compared to those without HTN during the same period. 
We also planned to compare overall survival (OS) and 
disease control rate (DCR) between the 2 groups.
Statistical methods
Appropriate descriptive statistics were used for 
demographic and tumor characteristics. Mean, median, 
standard deviation and minimum and maximum values 
were reported for continuous variables, while count and 
proportion were reported for non-continuous variables. 
PFS was defined as the time from the start of sorafenib 
therapy until disease progression or death from any cause 
Figure 4: Hypothetic activation of the renin-angiotensin system in patients who develop HTN during treatment with 
sorafenib.
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or last follow-up visit. OS was defined as the time-interval 
between the start of sorafenib therapy and death from any 
cause or last follow-up visit. PFS, OS and their two-sided 
95% confidence intervals (95% CI) were estimated by the 
Kaplan-Meier method and curves were compared by the 
log-rank test (at a significance level of 5%). DCR was 
defined as the proportion of patients to achieve complete 
response (CR), partial response (PR), stable disease (SD) 
or progressive disease (PD) according to mRECIST.
Estimated hazard ratios (HRs) and their two-sided 
95% CI were calculated using the Cox proportional-
hazard model. After univariate analysis, a multivariable 
Cox regression model (including age, gender, etiology, 
BCLC stage, ECOG performance status, toxicity, treatment 
duration and previous TACE) was used to adjust for these 
potential confounding factors. We investigated the potential 
association between HTN/blood electrolyte levels and 
disease progression, in particular using nonparametric tests 
to examine the relationship between changes in raw data 
and disease status of the 2 sequential blood tests.
All p values were based on two-sided testing and 
statistical analyses were performed using SAS statistical 
software version 9.3 (SAS Inc., Cary, NC, USA).
ACKNOWLEDGMENTS
The authors would like to thank Ursula Elbling for 
editorial assistance.
GRANT SUPPORT
No grant support
CONFLICTS OF INTEREST
There are no conflicts of interest to declare. The 
manuscript has not been published previously, and is not 
under consideration, in whole or in part, for publication 
elsewhere.
Author contributions
ACG conceived and designed the experiments. ES, 
MV, GM, GFF, GD, EG, MB, JC, LF, MS, NS, AG, GLB, 
LV, ST, SC and GLF collected and assembled the data. 
ACG and ES conceived the analysis and interpretation of 
data. ACG and ES wrote the manuscript. All authors gave 
the final approval of manuscript.
REFERENCES
1. Faloppi L, Scartozzi M, Maccaroni E, Di Pietro Paolo M, 
Berardi R, Del Prete M, Cascinu S. Evolving strategies for 
the treatment of hepatocellular carcinoma: From clinical-
guided to molecularly-tailored therapeutic options. Cancer 
Treat Rev. 2011; 37: 169-177.
2. Kane RC, Farrell AT, Madabushi R, Booth B, 
Chattopadhyay S, Sridhara R, Justice R, Pazdur R. 
Sorafenib for the treatment of unresectable hepatocellular 
carcinoma. Oncologist. 2009; 14: 95-100.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, 
Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner 
A, Schwartz M, Porta C, Zeuzem S, et al. Sorafenib in 
advanced hepatocellular carcinoma. N Engl J Med. 2008; 
359: 378-390.
4. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, 
Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, et al. 
Efficacy and safety of sorafenib in patients in the asia-
pacific region with advanced hepatocellular carcinoma: 
A phase III randomised, double-blind, placebo-controlled 
trial. Lancet Oncol. 2009; 10: 25-34.
5. Shao YY, Hsu CH, Cheng AL. Predictive biomarkers 
of antiangiogenic therapy for advanced hepatocellular 
carcinoma: Where are we? Liver Cancer. 2013; 2: 93-107.
6. Llovet JM, Peña CE, Lathia CD, Shan M, Meinhardt G, Bruix 
J; SHARP Investigators Study Group. Plasma biomarkers as 
predictors of outcome in patients with advanced hepatocellular 
carcinoma. Clin Cancer Res. 2012; 18: 2290-2300.
7. Casadei Gardini A, Marisi G, Scarpi E, Scartozzi M, 
Faloppi L, Silvestris N, Masi G, Vivaldi C, Tamberi S, 
Foschi FG, Tamburini E, Tenti E, Ricca S, et al. Effects 
of metformin on clinical outcome in diabetic patients 
with advanced HCC receiving sorafenib. Expert Opin 
Pharmacother 2015; 16: 2719-2725.
8. Launay-Vacher V, Deray G. Hypertension and proteinuria: 
a class-effect of antiangiogenic therapies. Anticancer Drugs. 
2009; 20: 81-82.
9. Chowdhury S, Spicer J, Harper P. Hypertension and 
targeted therapy: part 1. Bevacizumab. Targ Oncol. 2006; 
1: 104-108.
10. Chowdhury S, Spicer J, Harper P. Hypertension and 
targeted therapy: part 2. Small molecule inhibitors of 
VEGF. Targ Oncol. 2006; 1: 172-178.
11. Roodhart JM, Langenberg MH, Witteveen E, Voest EE. 
The molecular basis of class side effects due to treatment 
with inhibitors of the VEGF/VEGFR pathway. Curr Clin 
Pharmacol. 2008; 3: 132-143.
12. Humphreys BD, Atkins MB. Rapid development of 
hypertension by sorafenib: toxicity or target? Clin Cancer 
Res. 2009; 15: 5947-5949.
13. Rixe O, Billemont B, Izzedine H. Hypertension as a 
predictive factor of sunitinib activity. Ann Oncol. 2007; 18: 
1117.
14. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, 
Berardi R, Pierantoni C, Cascinu S. Arterial hypertension 
correlates with clinical outcome in colorectal cancer 
patients treated with first-line bevacizumab. Ann Oncol. 
2009; 20: 227-230.
15. Yang R, Thomas GR, Bunting S, Ko A, Ferrara N, Keyt B, 
Ross J, Jin H. Effects of vascular endothelial growth factor 
Oncotarget15251www.impactjournals.com/oncotarget
on hemodynamics and cardiac performance. J Cardiovasc 
Pharmacol. 1996; 27: 838-844.
16. Wei W, Jin H, Chen ZW, Zioncheck TF, Yim AP, He GW. 
Vascular endothelial growth factorinduced nitric oxide- and 
PGI2-dependent relaxation in human internal mammary 
arteries: a comparative study with KDR and Flt-1 selective 
mutants. J Cardiovasc Pharmacol. 2004; 44: 615-621.
17. Chu JS, Ge FJ, Zhang B, Wang Y, Silvestris N, Liu LJ, 
Zhao CH, Lin L, Brunetti AE, Fu YL, Wang J, Paradiso 
A, Xu JM. Expression and prognostic value of VEGFR-
2, PDGFR-β, and c-Met in advanced hepatocellular 
carcinoma. J Exp Clin Cancer Res. 2013; 32: 16.
18. Steeghs N, Gelderblom H, Roodt JO, Christensen O, 
Rajagopalan P, Hovens M, Putter H, Rabelink TJ, de 
Koning E. Hypertension and rarefaction during treatment 
with telatinib, a small molecule angiogenesis inhibitor. Clin 
Cancer Res. 2008; 14: 3470-3476.
19. Dechend R, Luft FC. Angiogenesis factors and 
preeclampsia. Nature Med. 2008; 14: 1187-1188.
20. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, 
Lynch M. Preclinical overview of sorafenib, a multikinase 
inhibitor that targets both raf and VEGF and PDGF receptor 
tyrosine kinase signaling. Mol Cancer Ther. 2008; 7: 3129-3140.
21. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, 
Walsh K, Franke TF, Papapetropoulos A, Sessa WC. 
Regulation of endothelium-derived nitric oxide production 
by the protein kinase akt. Nature. 1999; 399: 597-601.
22. Govers R, Rabelink TJ. Cellular regulation of endothelial 
nitric oxide synthase. Am J Physiol Renal Physiol. 2001; 
280: F193-206.
23. Lencioni R, Llovet JM. Modified RECIST (mRECIST) 
assessment for hepatocellular carcinoma. Semin Liver Dis. 
2010; 30: 52-60.
24. Merkus D, Sorop O, Houweling B, Boomsma F, van den 
Meiracker AH, Duncker DJ. NO and prostanoids blunt 
endothelin-mediated coronary vasoconstrictor influence in 
exercising swine. Am J Physiol Heart Circ Physiol. 2006; 
291: H2075-H2081.
25. Wiley KE, Davenport AP. Physiological antagonism of 
endothelin-1 in human conductance and resistance coronary 
artery. Br J Pharmacol. 2001; 133: 568-574.
26. Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser 
AH, van den Meiracker AH. Hypertension induced by 
the tyrosine kinase inhibitor sunitinib is associated with 
increased circulating endothelin-1 levels. Hypertension. 
2010; 56: 675-681.
27. Kappers MH, Smedts FM, Horn T, van Esch JH, Sleijfer 
S, Leijten F, Wesseling S, Strevens H, Jan Danser AH, 
van den Meiracker AH. The vascular endothelial growth 
factor receptor inhibitor sunitinib causes a preeclampsia-
like syndrome with activation of the endothelin system. 
Hypertension. 2011; 58: 295-302.
28. Estfan B, Byrne M, Kim R. Sorafenib in advanced 
hepatocellular carcinoma: hypertension as a potential 
surrogate marker for efficacy. Am J Clin Oncol. 2013; 36: 
319-324.
29. Akutsu N, Sasaki S, Takagi H, Motoya M, Shitani M, 
Igarashi M, Hirayama D, Wakasugi H, Yamamoto H, 
Kaneto H, Yonezawa K, Yawata A, Adachi T, et al. 
Development of hypertension within 2 weeks of 
initiation of sorafenib for advanced hepatocellular 
carcinoma is a predictor of efficacy. Int J ClinOncol. 
2015; 20: 105-110.
30. Ferrão FM, Lara LS, Lowe J. Renin-angiotensin system in 
the kidney: What is new? World J Nephrol. 2014; 3: 64-76.
